Halozyme Therapeutics Inc. Adjusts Outlook and Expands Delivery Technology Portfolio
Halozyme Therapeutics Inc. (NASDAQ: HALO) announced an upward revision of its revenue outlook for fiscal year 2025 and updated guidance for fiscal year 2026. The company cited strong performance of its proprietary hyaluronidase‑based delivery platform and anticipated growth in the diabetes, oncology, dermatology and drug‑delivery markets. The revised 2025 revenue range is now projected to be $XX‑$YY million (exact figures not provided in the source material), representing an increase over the prior guidance. For FY 2026, Halozyme expects continued expansion in its product pipeline, with particular emphasis on clinical development programs that leverage its recombinant human hyaluronidase and complementary enzymes.
In a separate corporate action, Halozyme completed the acquisition of Surf Bio, a specialty biotechnology company focused on drug‑delivery technologies. The transaction, valued at up to $400 million, is intended to augment Halozyme’s delivery platform and broaden its portfolio of enzymatic agents. The acquisition is expected to accelerate the development of next‑generation hyaluronidase derivatives and enhance the company’s ability to partner with pharmaceutical firms on novel drug‑delivery solutions.
The company’s strategic moves have attracted attention from investment analysts. Goldman Sachs reiterated a Sell recommendation for Halozyme on January 29, 2026, maintaining a price target of $58.00. Analyst Corinne Jenkins noted that the rating reflects concerns about competitive pressures and the company’s valuation relative to peers. The Price‑Earnings ratio of 14.67 places Halozyme at a moderate valuation level within the biotechnology sector, though the sell recommendation suggests that analysts expect a potential decline in share price.
Halozyme’s stock closed at $72.83 on January 27, 2026, after a trading session that followed the release of its updated guidance. The company’s market capitalization stood at $8.29 billion as of that date. The stock has traded between a 52‑week low of $47.50 and a 52‑week high of $79.50 since September 2025, indicating a relatively volatile performance over the past year.
The company’s core technology—recombinant human hyaluronidase—enables rapid, localized delivery of therapeutics by degrading hyaluronic acid in the extracellular matrix. Halozyme applies this technology across multiple therapeutic areas, including diabetes, oncology, dermatology, and general drug delivery. Recent regulatory developments, such as the U.S. Food and Drug Administration’s approval of a daratumumab‑based regimen that incorporates hyaluronidase, underscore the potential for Halozyme’s platform to be integrated into approved treatment protocols.
Halozyme remains headquartered in the United States and trades on the Nasdaq exchange. The company’s website, www.halozyme.com , provides further details on its product pipeline, partnership agreements, and corporate governance.
